Subscribe to RSS
DOI: 10.1055/a-1717-2234
Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data
Mepolizumab bei pädiatrischem schwerem Asthma: erste multizentrische Daten aus der Praxis![](https://www.thieme-connect.de/media/klinpaed/202205/lookinside/thumbnails/1495_10-1055-a-1717-2234-1.jpg)
Introduction
Asthma is associated with high morbidity and healthcare costs around the globe. Severe asthma in children is rare, and treatment with biologicals is seldom prescribed in pediatric asthma (Santos-Valente E., ERJ Open Res. 2021 Aug 16;7(3):00143-2021). Although global guidelines recommend using biologicals in severely asthmatic children, knowledge on real-life application in pediatrics is scarce. To change this situation, we aimed to analyze application and effect of anti-IL5 (Mepolizumab) therapy in childhood asthma in six pediatric centers in Germany.
Publication History
Article published online:
22 March 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany